Form 4: Astria CEO's Holdings Shift Post-BioCryst Merger

Astria Therapeutics CEO Jill C. Milne reports changes in beneficial ownership following the company's merger with BioCryst Pharmaceuticals, Inc.

Summary

• Astria Therapeutics, Inc. merged with Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc., on January 23, 2026.
• Astria Therapeutics, Inc. survived the merger and became a wholly-owned subsidiary of BioCryst.
• Each share of Astria common stock, excluding certain shares, was converted into the right to receive 0.59 of a share of BioCryst common stock and $8.55 in cash.
• Jill C. Milne, CEO and President, disposed of 4,377 shares of Astria common stock as a result of the merger.
• In-the-money stock options (exercise price less than $13.00) held by Milne were fully vested, exercisable, and canceled for a cash payment equal to the product of the number of shares subject to the option and the excess of $13.00 over the exercise price.
• Milne disposed of 195,000 stock options with an exercise price of $6.51 and 761,000 stock options with an exercise price of $6.41, both of which were in-the-money options.
• Out-of-the-money stock options (exercise price equal to or greater than $13.00) were canceled for no consideration and are not reported in this filing.

Sentiment

Score: 7

Explanation: The filing reports the expected outcome of a merger, which typically provides a clear exit strategy and value realization for shareholders and option holders, especially for in-the-money options. The cancellation of out-of-the-money options is a negative but standard practice in such transactions.

Positives

• The reporting person's in-the-money stock options were fully vested and converted to cash, providing liquidity and value realization.
• Common stock holdings were converted into a combination of BioCryst shares and cash, offering immediate value and continued equity exposure in the acquiring company.

Negatives

• Out-of-the-money stock options were canceled for no consideration, resulting in a loss of potential future value for those specific options.
• Astria Therapeutics, Inc. ceased to be an independent publicly traded entity, which means its specific equity no longer trades independently.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports a completed transaction.

Industry Context

This merger signifies consolidation within the biotechnology or pharmaceutical sector, where smaller companies like Astria Therapeutics are acquired by larger players like BioCryst Pharmaceuticals. Such acquisitions are common strategies for growth, portfolio expansion, and accessing new technologies or market positions within the industry.

Comparison to Industry Standards

• The merger consideration, combining cash and stock, is a common structure for acquisitions in the biotech industry, balancing immediate liquidity for shareholders with continued participation in the acquiring entity's future.
• The differentiated treatment of stock options, distinguishing between in-the-money and out-of-the-money options, is standard practice in M&A transactions to ensure fair value for vested options while canceling those with no intrinsic value.

Stakeholder Impact

• Shareholders of Astria Therapeutics received a combination of cash and BioCryst stock, realizing value from their investment.
• Option holders of Astria Therapeutics with in-the-money options received cash payouts, while those with out-of-the-money options had their options canceled without consideration.
• Astria Therapeutics became a wholly-owned subsidiary of BioCryst, implying integration and potential changes to employment terms for its employees, though not explicitly detailed here.

Key Dates

Keywords

Astria Therapeutics, BioCryst Pharmaceuticals, Merger, Form 4, Beneficial Ownership, Stock Options, Common Stock, Jill C. Milne, ATXS, Acquisition